腾盛博药-B:2025 中期报告

香港交易所
Sep 18

牛牛AI助理已提取核心讯息腾盛博药2025年上半年亏损收窄至人民币1.49亿元,较去年同期的2.83亿元大幅改善47.5%。期内研发开支为1.17亿元,同比减少7.3%;行政开支为5,823万元,同比减少26%。公司期末持有现金及银行结余20.75亿元。公司三项主要HBV功能性治愈2b期临床研究均已完成全部受试者招募。ENSURE研究队列4数据显示,接受过BRII-179给药的患者实现了更快及更高...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10